BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 17851759)

  • 1. A phase II study of pemetrexed and carboplatin in patients with locally advanced or metastatic breast cancer.
    Garin A; Manikhas A; Biakhov M; Chezhin M; Ivanchenko T; Krejcy K; Karaseva V; Tjulandin S
    Breast Cancer Res Treat; 2008 Jul; 110(2):309-15. PubMed ID: 17851759
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer.
    Seiwert TY; Connell PP; Mauer AM; Hoffman PC; George CM; Szeto L; Salgia R; Posther KE; Nguyen B; Haraf DJ; Vokes EE
    Clin Cancer Res; 2007 Jan; 13(2 Pt 1):515-22. PubMed ID: 17255273
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: a multicenter, randomized, phase II trial.
    Scagliotti GV; Kortsik C; Dark GG; Price A; Manegold C; Rosell R; O'Brien M; Peterson PM; Castellano D; Selvaggi G; Novello S; Blatter J; Kayitalire L; Crino L; Paz-Ares L
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):690-6. PubMed ID: 15701857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer.
    Smit EF; Burgers SA; Biesma B; Smit HJ; Eppinga P; Dingemans AM; Joerger M; Schellens JH; Vincent A; van Zandwijk N; Groen HJ
    J Clin Oncol; 2009 Apr; 27(12):2038-45. PubMed ID: 19307503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I study of pemetrexed (ALIMTA) and cyclophosphamide in patients with locally advanced or metastatic breast cancer.
    Dittrich C; Petruzelka L; Vodvarka P; Gneist M; Janku F; Kysela T; Melemed A; Latz J; Simms L; Krejcy K
    Clin Cancer Res; 2006 Dec; 12(23):7071-8. PubMed ID: 17145830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer.
    Matulonis UA; Horowitz NS; Campos SM; Lee H; Lee J; Krasner CN; Berlin S; Roche MR; Duska LR; Pereira L; Kendall D; Penson RT
    J Clin Oncol; 2008 Dec; 26(35):5761-6. PubMed ID: 19001330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized phase II trial of pemetrexed combined with either cisplatin or carboplatin in untreated extensive-stage small-cell lung cancer.
    Socinski MA; Weissman C; Hart LL; Beck JT; Choksi JK; Hanson JP; Prager D; Monberg MJ; Ye Z; Obasaju CK
    J Clin Oncol; 2006 Oct; 24(30):4840-7. PubMed ID: 17050869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced nonsmall cell lung cancer.
    Zinner RG; Fossella FV; Gladish GW; Glisson BS; Blumenschein GR; Papadimitrakopoulou VA; Pisters KM; Kim ES; Oh YW; Peeples BO; Ye Z; Curiel RE; Obasaju CK; Hong WK; Herbst RS
    Cancer; 2005 Dec; 104(11):2449-56. PubMed ID: 16258975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer.
    Socinski MA; Smit EF; Lorigan P; Konduri K; Reck M; Szczesna A; Blakely J; Serwatowski P; Karaseva NA; Ciuleanu T; Jassem J; Dediu M; Hong S; Visseren-Grul C; Hanauske AR; Obasaju CK; Guba SC; Thatcher N
    J Clin Oncol; 2009 Oct; 27(28):4787-92. PubMed ID: 19720897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma.
    Ceresoli GL; Zucali PA; Favaretto AG; Grossi F; Bidoli P; Del Conte G; Ceribelli A; Bearz A; Morenghi E; Cavina R; Marangolo M; Parra HJ; Santoro A
    J Clin Oncol; 2006 Mar; 24(9):1443-8. PubMed ID: 16549838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, double-blind, phase II study of two doses of pemetrexed as first-line chemotherapy for advanced breast cancer.
    Llombart-Cussac A; Martin M; Harbeck N; Anghel RM; Eniu AE; Verrill MW; Neven P; De Grève J; Melemed AS; Clark R; Simms L; Kaiser CJ; Ma D
    Clin Cancer Res; 2007 Jun; 13(12):3652-9. PubMed ID: 17575230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pemetrexed and cisplatin in patients with advanced gastric cancer: a Korean cancer study group multicenter phase II study.
    Kim YH; Chung HC; Kang WK; Park SR; Kim CS; Kim TY; Shin SW; Park BJ; Cha SJ; Bang YJ
    Cancer Chemother Pharmacol; 2008 Jul; 62(2):263-70. PubMed ID: 17960386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I/II study of pemetrexed and vinorelbine in patients with non-small cell lung cancer.
    Clarke SJ; Boyer MJ; Millward M; Underhill C; Moylan E; Yip D; White S; Childs A; Beale P; Latz J; Suri A; Iglesias JL
    Lung Cancer; 2005 Sep; 49(3):401-12. PubMed ID: 15923057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II trial combining paclitaxel with 24-hour infusion cisplatin for chemotherapy-naïve patients with locally advanced or metastatic breast carcinoma.
    Hsu C; Huang CS; Chao TY; Lu YS; Bu CF; Chen MM; Chang KJ; Cheng AL
    Cancer; 2002 Nov; 95(10):2044-50. PubMed ID: 12412156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic evaluation of platinum derived from cisplatin administered alone and with pemetrexed in head and neck cancer patients.
    Specenier PM; Ciuleanu T; Latz JE; Musib LC; Darstein CL; Vermorken JB
    Cancer Chemother Pharmacol; 2009 Jul; 64(2):233-41. PubMed ID: 19011858
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized phase II study of pemetrexed in combination with cisplatin or carboplatin as first-line therapy for patients with locally advanced or metastatic non-small-cell lung cancer.
    Schuette WH; Gröschel A; Sebastian M; Andreas S; Müller T; Schneller F; Guetz S; Eschbach C; Bohnet S; Leschinger MI; Reck M
    Clin Lung Cancer; 2013 May; 14(3):215-23. PubMed ID: 23332288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium.
    Sweeney CJ; Roth BJ; Kabbinavar FF; Vaughn DJ; Arning M; Curiel RE; Obasaju CK; Wang Y; Nicol SJ; Kaufman DS
    J Clin Oncol; 2006 Jul; 24(21):3451-7. PubMed ID: 16849761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer.
    Patel JD; Hensing TA; Rademaker A; Hart EM; Blum MG; Milton DT; Bonomi PD
    J Clin Oncol; 2009 Jul; 27(20):3284-9. PubMed ID: 19433684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of carboplatin and pemetrexed in advanced non-squamous, non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0902.
    Kim YH; Hirabayashi M; Togashi Y; Hirano K; Tomii K; Masago K; Kaneda T; Yoshimatsu H; Otsuka K; Mio T; Tomioka H; Suzuki Y; Mishima M
    Cancer Chemother Pharmacol; 2012 Aug; 70(2):271-6. PubMed ID: 22752216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Results of a phase II study of pemetrexed as first-line chemotherapy in patients with advanced or metastatic breast cancer.
    Robert NJ; Conkling PR; O'Rourke MA; Kuefler PR; McIntyre KJ; Zhan F; Asmar L; Wang Y; Shonukan OO; O'Shaughnessy JA
    Breast Cancer Res Treat; 2011 Feb; 126(1):101-8. PubMed ID: 21188632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.